Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Preparation and preclinical study of [68Ga]‌Ga-(Pip)-Nle-CycMSHhex: Optimized production with an in-house 68Ge/68Ga generator

Document Type : Original Article

Authors
Sepideh Shafiei 1
Leyla Akbari 2
Arezoo Karimian 3
Samaneh Zolghadri 1
Mostafa Erfani 1
Azadeh Mikaeili 1
Zhila Fallah 1
Hassan Yousefnia 1
1 Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
2 Nuclear Engineering Department, Shiraz University, Shiraz, Iran
3 Faculty of Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran
10.22034/irjnm.2024.129486.1590
Abstract
Introduction: The early diagnosis of melanoma is crucial for treatment and management of this aggressive malignancy.   The present study describes the preparation and preclinical evaluation of 68Ga-radiolabeled DOTA-4amino-(I-carboxymethyl) piperidine (Pip)-Nle-cysMSHhex peptide ([68Ga]Ga-CCZ01048) as a potential aide for PET imaging and early diagnosis of malignant melanoma.
Methods: Various parameters were assessed to optimize the final preparation processes. The radiochemical purity of the final complex was checked using RTLC and HPLC methods. The stability of the radiolabeled complex was studied at 15, 30, 60 and 120-min post-injection. The partition coefficient was also studied. Cellular studies of the labeled peptide were measured using B16F10 cells at different post-treatment intervals. The biodistribution of the labeled compound was evaluated using normal and tumor-bearing mice.
Results: [68Ga]­Ga-(Pip)-Nle-cysMSHhex radiolabeled complex was prepared with a specific activity of 118.4 TBq/mmol and radiochemical purity > 99% at optimized conditions. The results of stability studies show that the radiolabeled compound is stable in PBS buffer and human serum after 120 min. The cellular studies demonstrated that a binding affinity of [68Ga]­Ga-(Pip)-Nle-cysMSHhex on B16F10 cells and the internalization of the complex increased from about 31% in 30 min to 62% in 240 min post-treatment. The biodistribution studies showed excretion of major portion of the tracer through the kidneys. The remainder of the tracer mostly accumulated at the tumor site. No significant uptake in non-target organs was observed at any interval following injection.
Conclusion: The [68Ga]­Ga-(Pip)-Nle-cysMSHhex radiolabeled complex has the potential as a PET imaging agent for evaluation of metastatic malignant melanoma.
Keywords
Melanoma
[68Ga]Ga-CCZ01048
α-MSH
PET
Biodistribution
Subjects
  1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006 Jul 6;355(1):51-65.
  2. Raposinho PD, Correia JD, Oliveira MC, Santos I. Melanocortin-1 receptor-targeting with radiolabeled cyclic α-melanocyte-stimulating hormone analogs for melanoma imaging. Biopolymers. 2010;94(6):820-9.
  3. Miao Y, Quinn TP. Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy. J Nucl Med. 2021 Mar;62(3):313-8. 
  4. Kálmán-Szabó I, Bunda S, Lihi N, Szaniszló Z, Szikra D, Szabó Péliné J, Fekete A, Gyuricza B, Szücs D, Papp G, Trencsényi G, Kálmán FK. 61Cu-Labelled radiodiagnostics of melanoma with NAPamide-targeted radiopharmaceutical. Int J Pharm. 2023 Feb 5;632:122527.
  5. Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291-7.
  6. Zhang C, Lin KS, Bénard F. Molecular imaging and radionuclide therapy of melanoma targeting the melanocortin 1 receptor. Mol Imaging. 2017 Jan-Dec;16:1536012117737919.
  7. Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther. 2018 Jun 7;7:35-49.
  8. Zhang C, Zhang Z, Lin KS, Lau J, Zeisler J, Colpo N, Perrin DM, Bénard F. Melanoma imaging using 18F-Labeled α-melanocyte-stimulating hormone derivatives with positron emission tomography. Mol Pharm. 2018 Jun 4;15(6):2116-22.
  9. Gai Y, Yuan L, Sun L, Li H, Li M, Fang H, Altine B, Liu Q, Zhang Y, Zeng D, Lan X. Comparison of Al18F- and 68Ga-labeled NOTA-PEG4-LLP2A for PET imaging of very late antigen-4 in melanoma. J Biol Inorg Chem. 2020 Feb;25(1):99-108.
  10. Zhang C, Zhang Z, Merkens H, Zeisler J, Colpo N, Hundal-Jabal N, Perrin DM, Lin KS, Bénard F. 18F-Labeled cyclized α-melanocyte-stimulating hormone derivatives for imaging human melanoma xenograft with positron emission tomography. Sci Rep. 2019 Sep 19;9(1):13575. 
  11. Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014 Mar;23(1):11-6.
  12. Chung H, Lee JH, Jeong D, Han IO, Oh ES. Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression. J Biol Chem. 2012 Jun 1;287(23):19326-35.
  13. Rosenkranz AA, Slastnikova TA, Durymanov MO, Sobolev AS. Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc). 2013 Nov;78(11):1228-37. 
  14. Yang H, Gao F, McNeil B, Zhang C, Yuan Z, Zeisler S, Kumlin J, Zeisler J, Bénard F, Ramogida C, Schaffer P. Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide. EJNMMI Radiopharm Chem. 2021 Jan 13;6(1):3. 
  15. Holder JR, Haskell-Luevano C. Melanocortin ligands: 30 years of structure-activity relationship (SAR) studies. Med Res Rev. 2004 May;24(3):325-56.
  16. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004 Jan;45(1):116-23.
  17. Cody WL, Mahoney M, Knittel JJ, Hruby VJ, Castrucci AM, Hadley ME. Cyclic melanotropins. 9. 7-D-Phenylalanine analogues of the active-site sequence. J Med Chem. 1985 May;28(5):583-8.
  18. Guo H, Yang J, Gallazzi F, Miao Y. Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides. J Nucl Med. 2011 Apr;52(4):608-16.
  19. Guo H, Gallazzi F, Miao Y. Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake. Bioconjug Chem. 2012 Jun 20;23(6):1341-8. 
  20. Morais M, Oliveira BL, Correia JD, Oliveira MC, Jiménez MA, Santos I, Raposinho PD. Influence of the bifunctional chelator on the pharmacokinetic properties of 99mTc(CO)3-labeled cyclic α-melanocyte stimulating hormone analog. J Med Chem. 2013 Mar 14;56(5):1961-73.
  21. Wei W, Ehlerding EB, Lan X, Luo Q, Cai W. PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):132-50.
  22. Guo H, Miao Y. Cu-64-labeled lactam bridge-cyclized α-MSH peptides for PET imaging of melanoma. Mol Pharm. 2012 Aug 6;9(8):2322-30. 
  23. Nagy G, Dénes N, Kis A, Szabó JP, Berényi E, Garai I, Bai P, Hajdu I, Szikra D, Trencsényi G. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific 68Ga- and 44Sc-labeled DOTA-NAPamide in melanoma imaging. Eur J Pharm Sci. 2017 Aug 30;106:336-44.
  24. Zhang C, Zhang Z, Lin KS, Pan J, Dude I, Hundal-Jabal N, Colpo N, Bénard F. Preclinical melanoma imaging with 68Ga-labeled α-melanocyte-stimulating hormone derivatives using PET. Theranostics. 2017 Feb 8;7(4):805-3.
  25. Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A. Clinical indications for Gallium-68 positron emission tomography imaging. Eur J Surg Oncol. 2009 Jun;35(6):561-7.
  26. Burke BP, Archibald SJ. Labeling with Gallium‐68. Scott P, Kilbourn M, editors. Handbook of radiopharmaceuticals: methodology and applications. 1st ed. John Wiley & Sons. 2020 Dec 21. P. 291-323.
  27. Ghoncheh M, Koohi F, Salehiniya H. Epidemiology and trend of skin cancer incidence in southern Iran. J Dermatol Cosmet. 2015 Jul 10;6(2):85-92.
  28. Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018 Mar;47(3):309-16.
  29. Pakzad R, Soltani S, Salehiniya H. Epidemiology and trend in skin cancer mortality in Iran. J Res Med Sci. 2015 Sep;20(9):921.
  30. Afzali M, Mirzaei M, Saadati H, Mazloomi-Mahmood-Abadi SS. Epidemiology of skin cancer and changes in its trends in Iran. Feyz Med Sci J. 2013 Nov 1;17(5): 501.
  31. Keyghobadi N, Rafiemanesh H, Mohammadian-Hafshejani A, Enayatrad M, Salehiniya H. Epidemiology and trend of cancers in the province of Kerman: southeast of Iran. Asian Pac J Cancer Prev. 2015;16(4):1409-13. 
  32. Sharifi M, Yousefnia H, Bahrami-Samani A, Jalilian AR, Zolghadri S, Alirezapour B, Geramifar P, Maus S, Beiki D. Optimized production, quality control, biological evaluation and PET/CT imaging of 68Ga-PSMA-617 in breast adenocarcinoma model. Radiochim Acta. 2017 May 1;105(5):399-407.
  33. Karimkhani S, Yousefnia H, Faghihi R, Gramifar P, Parishan MR. Calculation of Gallium-68 dose factors for [68Ga] DOTATATE injected patients: a comparison with OLINDA Database. J Nucl Sci Appl. 2022; 2(2):30-40.
  34. Yousefnia H, Zolghadri S, Jalilian AR. Absorbed dose of human organs after injection of 68Ga-EDTMP: estimation from biodistribution data in wild-type rats. Fron Biomed Technol. 2018 Dec 30;5(3-4):63-8.
  35. Zolghadri S, Badipa F, Amraee N, Alirezapour B, Beiki D, Yousefnia H. Development and evaluation of [64Cu] Cu-DOTATATE for clinical applications. Iran J Nucl Med.  2023 Jul 1;31(2):157-66.